Allurion Technologies, INC. (ALUR) — SEC Filings
Latest SEC filings for Allurion Technologies, INC.. Recent 10-K filing on Mar 30, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.
View Allurion Technologies, INC. on SEC EDGAR
Overview
Allurion Technologies, INC. (ALUR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 30, 2026: Allurion Technologies, Inc. (ALUR) is pioneering metabolically healthy weight loss with its Allurion Program, featuring the Allurion Smart Capsule, the world's first and only swallowable, Procedureless™ intragastric balloon. The company reported that over 200,000 patients have been treated commercia
Sentiment Summary
Across 1 filings, the sentiment breakdown is: 1 bullish. The dominant filing sentiment for Allurion Technologies, INC. is bullish.
Filing Type Overview
Allurion Technologies, INC. (ALUR) has filed 1 10-K with the SEC between Mar 2026.
Recent Filings (1)
-
Allurion Secures FDA Nod for Smart Capsule, Eyes US Market Expansion
— 10-K · Mar 30, 2026 Risk: medium
Allurion Technologies, Inc. (ALUR) is pioneering metabolically healthy weight loss with its Allurion Program, featuring the Allurion Smart Capsule, the world's
Risk Profile
Risk Assessment: Of ALUR's 1 recent filings, 0 were flagged as high-risk, 1 as medium-risk, and 0 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Industry Context
Allurion operates in the highly competitive and growing medical device market for obesity and weight management. Key trends include the increasing prevalence of obesity globally, a growing demand for less invasive and more convenient treatment options, and advancements in digital health and remote patient monitoring. Competitors range from pharmaceutical companies developing weight-loss drugs to other medical device manufacturers offering surgical and non-surgical interventions.
Top Tags
Medical Devices (1) · Weight Loss (1) · FDA Approval (1) · Biotechnology (1) · Healthcare Innovation (1) · Obesity Treatment (1) · AI in Healthcare (1)
Key Numbers
- Market Value of Non-Affiliate Common Equity: $20,666,535 — As of June 30, 2025, indicating a relatively small market capitalization.
- Patients Treated Commercially: 200,000 — In over 50 countries outside the United States, demonstrating international adoption.
- Capital Raised: $5.0 million — Through the November 2025 Securities Purchase Agreement, providing additional funding.
- Reverse Stock Split Ratio: 1-for-25 — Effected in January 2025, impacting share count and per-share metrics.
- Common Stock Outstanding: 14,994,486 — As of March 20, 2026, post-reverse stock split.
- Countries of Commercial Operation: 50 — Outside the U.S., showcasing global reach prior to U.S. FDA approval.
- Average Balloon Residence Time: 15.3 weeks — Observed for the Allurion Gastric Balloon System, indicating short-term use.
- BMI Range for FDA Indication: 30 kg/m2 and 40 kg/m2 — Specific target patient population for the Allurion Gastric Balloon System in the U.S.
- Shares Issued in Private Placement: 2,994,012 — Part of the November 2025 Securities Purchase Agreement, increasing share count.
- Private Placement Share Price: $1.67 — Price per share and warrant in the November 2025 Securities Purchase Agreement.
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Allurion Technologies, INC. (ALUR)?
Allurion Technologies, INC. has 1 recent SEC filings from Mar 2026, including 1 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of ALUR filings?
Across 1 filings, the sentiment breakdown is: 1 bullish. The dominant sentiment is bullish.
Where can I find Allurion Technologies, INC. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Allurion Technologies, INC. (ALUR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Allurion Technologies, INC.?
Key financial highlights from Allurion Technologies, INC.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for ALUR?
The investment thesis for ALUR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Allurion Technologies, INC.?
Executive information for Allurion Technologies, INC. is extracted from SEC filings as they are enriched with AI analysis.
What are the main risk factors for Allurion Technologies, INC. stock?
Of ALUR's 1 assessed filings, 0 were flagged high-risk, 1 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Allurion Technologies, INC.?
Forward guidance and predictions for Allurion Technologies, INC. are extracted from SEC filings as they are enriched.